miR‑501‑3p sensitizes glioma cells to cisplatin by targeting MYCN

Abstract

Cisplatin, a commonly used chemotherapeutic agent for glioma patients, treatment often leads to chemoresistance. Accumulating evidence has demosntrated that microRNA (miRNA/miR) is involved in drug resistance of glioma cells. Nevertheless, the role of miR-501-3p in glioma cell resistance to cisplatin is unclear. In the present study, it was revealed that miR-501-3p expression was decreased in glioma tissues and further underexpressed in cisplatin-resistant glioma cells compared with wild-type (WT) glioma cells. Furthermore, cisplatin treatment inhibited the level of miR-501-3p in a time-dependent way. Ectopic expression of miR-501-3p suppressed glioma cell growth and invasion, but increased cisplatin-resistant glioma cell apoptosis. Furthermore, miR-501-3p sensitized glioma cells to cisplatin-induced proliferation arrest and death. Mechanistically, it was demonstrated that miR-501-3p targeted MYCN in glioma cells. In addition, it was revealed that miR-501-3p inhibited MYCN expression by a luciferase reporter assay and reverse transcription-quantitativepolymerasechainreaction.Notably, restoration of MYCN reversed the effects of miR-501-3p in cisplatin-resistant glioma cells. In conclusion, these results suggested that miR-501-3p may serve a promising marker for cisplatin resistance.